Urogenital symptoms in mitochondrial disease: overlooked and undertreated.

bladder symptoms bowel symptoms lower gastrointestinal tract symptoms lower urinary tract symptoms mitochondrial disease sexual dysfunction urogenital symptoms

Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
08 2019
Historique:
received: 28 11 2018
accepted: 11 03 2019
pubmed: 19 3 2019
medline: 8 8 2020
entrez: 19 3 2019
Statut: ppublish

Résumé

Bowel symptoms are well documented in mitochondrial disease. However, data concerning other pelvic organs is limited. A large case-control study has therefore been undertaken to determine the presence of lower urinary tract symptoms (LUTS) and sexual dysfunction in adults with genetically confirmed mitochondrial disease. Adults with genetically confirmed mitochondrial disease and control subjects were recruited from a specialist mitochondrial clinic. The presence and severity of LUTS and their impact on quality of life, in addition to sexual dysfunction and bowel symptoms, were captured using four validated questionnaires. Subgroup analysis was undertaken in patients harbouring the m.3243A>G MT-TL1 mitochondrial DNA mutation. A subset of patients underwent urodynamic studies to further characterize their LUTS. Data from 58 patients and 19 controls (gender and age matched) were collected. Adults with mitochondrial disease had significantly more overactive bladder (81.5% vs. 56.3%, P = 0.039) and low stream (34.5% vs. 5.3%, P = 0.013) urinary symptoms than controls. Urodynamic studies in 10 patients confirmed that bladder storage symptoms predominate. Despite high rates of LUTS, none of the patient group was receiving treatment. Female patients and those harbouring the m.3243A>G MT-TL1 mutation experienced significantly more sexual dysfunction than controls (53.1% vs. 11.1%, P = 0.026, and 66.7% vs. 26.3%, P = 0.011, respectively). Lower urinary tract symptoms are common but undertreated in adult mitochondrial disease, and female patients and those harbouring the m.3243A>G MT-TL1 mutation experience sexual dysfunction. Given their impact on quality of life, screening for and treating LUTS and sexual dysfunction in adults with mitochondrial disease are strongly recommended.

Sections du résumé

BACKGROUND AND PURPOSE
Bowel symptoms are well documented in mitochondrial disease. However, data concerning other pelvic organs is limited. A large case-control study has therefore been undertaken to determine the presence of lower urinary tract symptoms (LUTS) and sexual dysfunction in adults with genetically confirmed mitochondrial disease.
METHODS
Adults with genetically confirmed mitochondrial disease and control subjects were recruited from a specialist mitochondrial clinic. The presence and severity of LUTS and their impact on quality of life, in addition to sexual dysfunction and bowel symptoms, were captured using four validated questionnaires. Subgroup analysis was undertaken in patients harbouring the m.3243A>G MT-TL1 mitochondrial DNA mutation. A subset of patients underwent urodynamic studies to further characterize their LUTS.
RESULTS
Data from 58 patients and 19 controls (gender and age matched) were collected. Adults with mitochondrial disease had significantly more overactive bladder (81.5% vs. 56.3%, P = 0.039) and low stream (34.5% vs. 5.3%, P = 0.013) urinary symptoms than controls. Urodynamic studies in 10 patients confirmed that bladder storage symptoms predominate. Despite high rates of LUTS, none of the patient group was receiving treatment. Female patients and those harbouring the m.3243A>G MT-TL1 mutation experienced significantly more sexual dysfunction than controls (53.1% vs. 11.1%, P = 0.026, and 66.7% vs. 26.3%, P = 0.011, respectively).
CONCLUSIONS
Lower urinary tract symptoms are common but undertreated in adult mitochondrial disease, and female patients and those harbouring the m.3243A>G MT-TL1 mutation experience sexual dysfunction. Given their impact on quality of life, screening for and treating LUTS and sexual dysfunction in adults with mitochondrial disease are strongly recommended.

Identifiants

pubmed: 30884027
doi: 10.1111/ene.13952
pmc: PMC6767393
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1111-1120

Subventions

Organisme : Medical Research Council
ID : G0601943
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K000608/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S002065/1
Pays : United Kingdom

Informations de copyright

© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

Références

J Neurol Neurosurg Psychiatry. 1987 Nov;50(11):1475-81
pubmed: 2826704
Arch Dis Child. 2003 Apr;88(4):347-9
pubmed: 12651768
J Urol. 2008 Dec;180(6):2592-8
pubmed: 18950816
J Intern Med. 2003 Mar;253(3):381-5
pubmed: 12603507
Arch Neurol. 2010 Aug;67(8):976-9
pubmed: 20697048
Neth J Med. 2008 Jan;66(1):18-22
pubmed: 18219063
J Sex Marital Ther. 2000 Jan-Mar;26(1):25-40
pubmed: 10693114
Diabetes Care. 2017 Jan;40(1):136-154
pubmed: 27999003
Ann Neurol. 2015 May;77(5):753-9
pubmed: 25652200
Spinal Cord. 2006 Oct;44(10):625-31
pubmed: 16344850
Orphanet J Rare Dis. 2017 Sep 26;12(1):158
pubmed: 28950889
Lancet Neurol. 2015 Jul;14(7):720-32
pubmed: 26067125
Eur J Neurol. 2017 Feb;24(2):255-261
pubmed: 27869334
Nat Rev Dis Primers. 2016 May 05;2:16031
pubmed: 27147135
Gastroenterol Clin North Am. 2003 Sep;32(3):789-817, v
pubmed: 14562575
Urology. 2008 Apr;71(4):646-56
pubmed: 18313122
Neurology. 2006 Jun 27;66(12):1932-4
pubmed: 16801664
Neurology. 1994 Apr;44(4):721-7
pubmed: 8164833
Diabetes Metab. 2004 Feb;30(1):61-6
pubmed: 15029099
J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):936-8
pubmed: 23355809

Auteurs

O V Poole (OV)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

T Uchiyama (T)

Department of Uro-Neurology, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.
Department of Neurology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
Department of Neurology, School of Medicine, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.

I Skorupinska (I)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

M Skorupinska (M)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

L Germain (L)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

D Kozyra (D)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

S Holmes (S)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

N James (N)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

E Bugiardini (E)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

C Woodward (C)

Neurogenetics Unit, National Hospital for Neurology and Neurosurgery, London, UK.

R Quinlivan (R)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.
Dubowitz Neuromuscular Centre, Great Ormond Street Hospital, London, UK.

A Emmanuel (A)

Gastro-Intestinal Physiology Unit, University College London Hospital, London, UK.

M G Hanna (MG)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

J N Panicker (JN)

Department of Uro-Neurology, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

R D S Pitceathly (RDS)

MRC Centre for Neuromuscular Diseases, UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH